vs
Side-by-side financial comparison of CENTURY ALUMINUM CO (CENX) and HAEMONETICS CORP (HAE). Click either name above to swap in a different company.
CENTURY ALUMINUM CO is the larger business by last-quarter revenue ($633.7M vs $339.0M, roughly 1.9× HAEMONETICS CORP). HAEMONETICS CORP runs the higher net margin — 13.2% vs 0.3%, a 12.9% gap on every dollar of revenue. On growth, CENTURY ALUMINUM CO posted the faster year-over-year revenue change (0.4% vs -2.7%). HAEMONETICS CORP produced more free cash flow last quarter ($87.2M vs $67.7M). Over the past eight quarters, CENTURY ALUMINUM CO's revenue compounded faster (13.8% CAGR vs 0.4%).
Century Aluminum Company is a US-based producer of primary aluminum, with aluminum plants in Kentucky, South Carolina and Iceland. It is the largest producer of primary aluminum in the United States. The company is a publicly held corporation listed on the NASDAQ. The headquarters is at One South Wacker in Chicago.
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
CENX vs HAE — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $633.7M | $339.0M |
| Net Profit | $1.8M | $44.7M |
| Gross Margin | 13.0% | 59.7% |
| Operating Margin | 5.2% | 19.9% |
| Net Margin | 0.3% | 13.2% |
| Revenue YoY | 0.4% | -2.7% |
| Net Profit YoY | -96.0% | 19.3% |
| EPS (diluted) | $0.03 | $0.95 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $633.7M | $339.0M | ||
| Q3 25 | $632.2M | $327.3M | ||
| Q2 25 | $628.1M | $321.4M | ||
| Q1 25 | $633.9M | $330.6M | ||
| Q4 24 | $630.9M | $348.5M | ||
| Q3 24 | $539.1M | $345.5M | ||
| Q2 24 | $560.8M | $336.2M | ||
| Q1 24 | $489.5M | — |
| Q4 25 | $1.8M | $44.7M | ||
| Q3 25 | $14.9M | $38.7M | ||
| Q2 25 | $-4.6M | $34.0M | ||
| Q1 25 | $29.7M | $58.0M | ||
| Q4 24 | $45.2M | $37.5M | ||
| Q3 24 | $47.3M | $33.8M | ||
| Q2 24 | $-2.5M | $38.4M | ||
| Q1 24 | $246.8M | — |
| Q4 25 | 13.0% | 59.7% | ||
| Q3 25 | 12.2% | 59.5% | ||
| Q2 25 | 5.8% | 59.8% | ||
| Q1 25 | 9.6% | 58.4% | ||
| Q4 24 | 10.5% | 55.5% | ||
| Q3 24 | 15.2% | 54.2% | ||
| Q2 24 | 3.6% | 52.0% | ||
| Q1 24 | 3.4% | — |
| Q4 25 | 5.2% | 19.9% | ||
| Q3 25 | 9.2% | 17.9% | ||
| Q2 25 | 3.3% | 16.8% | ||
| Q1 25 | 7.3% | 21.6% | ||
| Q4 24 | 7.8% | 16.9% | ||
| Q3 24 | 11.8% | 15.0% | ||
| Q2 24 | 1.1% | 11.8% | ||
| Q1 24 | 0.4% | — |
| Q4 25 | 0.3% | 13.2% | ||
| Q3 25 | 2.4% | 11.8% | ||
| Q2 25 | -0.7% | 10.6% | ||
| Q1 25 | 4.7% | 17.5% | ||
| Q4 24 | 7.2% | 10.8% | ||
| Q3 24 | 8.8% | 9.8% | ||
| Q2 24 | -0.4% | 11.4% | ||
| Q1 24 | 50.4% | — |
| Q4 25 | $0.03 | $0.95 | ||
| Q3 25 | $0.15 | $0.81 | ||
| Q2 25 | $-0.05 | $0.70 | ||
| Q1 25 | $0.29 | $1.17 | ||
| Q4 24 | $0.58 | $0.74 | ||
| Q3 24 | $0.46 | $0.66 | ||
| Q2 24 | $-0.03 | $0.74 | ||
| Q1 24 | $2.26 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $134.2M | $363.4M |
| Total DebtLower is stronger | — | $1.2B |
| Stockholders' EquityBook value | $805.6M | $911.5M |
| Total Assets | $2.3B | $2.5B |
| Debt / EquityLower = less leverage | — | 1.34× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $134.2M | $363.4M | ||
| Q3 25 | $151.4M | $296.4M | ||
| Q2 25 | $40.7M | $292.9M | ||
| Q1 25 | $44.9M | $306.8M | ||
| Q4 24 | $32.9M | $320.8M | ||
| Q3 24 | — | $299.3M | ||
| Q2 24 | $41.3M | $344.4M | ||
| Q1 24 | $93.5M | — |
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $805.6M | $911.5M | ||
| Q3 25 | $741.8M | $849.2M | ||
| Q2 25 | $724.4M | $882.3M | ||
| Q1 25 | $726.3M | $820.8M | ||
| Q4 24 | $694.4M | $906.9M | ||
| Q3 24 | $628.5M | $878.9M | ||
| Q2 24 | $601.5M | $905.4M | ||
| Q1 24 | $601.5M | — |
| Q4 25 | $2.3B | $2.5B | ||
| Q3 25 | $2.1B | $2.4B | ||
| Q2 25 | $1.9B | $2.5B | ||
| Q1 25 | $2.0B | $2.5B | ||
| Q4 24 | $1.9B | $2.5B | ||
| Q3 24 | $2.1B | $2.5B | ||
| Q2 24 | $1.8B | $2.5B | ||
| Q1 24 | $1.8B | — |
| Q4 25 | — | 1.34× | ||
| Q3 25 | — | 1.44× | ||
| Q2 25 | — | 1.39× | ||
| Q1 25 | — | 1.49× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $102.8M | $93.6M |
| Free Cash FlowOCF − Capex | $67.7M | $87.2M |
| FCF MarginFCF / Revenue | 10.7% | 25.7% |
| Capex IntensityCapex / Revenue | 5.5% | 1.9% |
| Cash ConversionOCF / Net Profit | 57.11× | 2.09× |
| TTM Free Cash FlowTrailing 4 quarters | $84.8M | $308.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $102.8M | $93.6M | ||
| Q3 25 | $2.0M | $111.3M | ||
| Q2 25 | $7.9M | $17.4M | ||
| Q1 25 | $72.3M | $116.6M | ||
| Q4 24 | $-41.4M | $43.8M | ||
| Q3 24 | $20.1M | $48.8M | ||
| Q2 24 | $11.5M | $-27.4M | ||
| Q1 24 | $-14.8M | — |
| Q4 25 | $67.7M | $87.2M | ||
| Q3 25 | $-18.1M | $106.3M | ||
| Q2 25 | $-15.9M | $13.6M | ||
| Q1 25 | $51.1M | $100.9M | ||
| Q4 24 | $-54.6M | $35.2M | ||
| Q3 24 | $-2.4M | $39.4M | ||
| Q2 24 | $-5.4M | $-33.1M | ||
| Q1 24 | $-44.5M | — |
| Q4 25 | 10.7% | 25.7% | ||
| Q3 25 | -2.9% | 32.5% | ||
| Q2 25 | -2.5% | 4.2% | ||
| Q1 25 | 8.1% | 30.5% | ||
| Q4 24 | -8.7% | 10.1% | ||
| Q3 24 | -0.4% | 11.4% | ||
| Q2 24 | -1.0% | -9.8% | ||
| Q1 24 | -9.1% | — |
| Q4 25 | 5.5% | 1.9% | ||
| Q3 25 | 3.2% | 1.5% | ||
| Q2 25 | 3.8% | 1.2% | ||
| Q1 25 | 3.3% | 4.7% | ||
| Q4 24 | 2.1% | 2.5% | ||
| Q3 24 | 4.2% | 2.7% | ||
| Q2 24 | 3.0% | 1.7% | ||
| Q1 24 | 6.1% | — |
| Q4 25 | 57.11× | 2.09× | ||
| Q3 25 | 0.13× | 2.88× | ||
| Q2 25 | — | 0.51× | ||
| Q1 25 | 2.43× | 2.01× | ||
| Q4 24 | -0.92× | 1.17× | ||
| Q3 24 | 0.42× | 1.44× | ||
| Q2 24 | — | -0.71× | ||
| Q1 24 | -0.06× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CENX
| Aluminum | $566.3M | 89% |
| Alumina | $67.4M | 11% |
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
